Brief: Anges MG receives IND approval from FDA
25/04/2017 04:15
April 25 (Reuters) - Anges MG Inc 4563.T
* Says it received investigational new drug (IND) approval
from FDA, for a clinical trial with F-kappaB decoy oligo DNA in
U.S, for treatment of discogenic lower back pain
Source text in Japanese:https://goo.gl/qccLX9
Further company coverage: 4563.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; 82555111; Reuters
Messaging: Pingping.Li@thomsonreuters.com@reuters.net))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001